DE

447.26

-4.91%↓

FDX

215.59

-12.15%↓

PAYX

153.66

-0.92%↓

CPRT

56.65

-1.58%↓

HEICA

203.75

-4.28%↓

DE

447.26

-4.91%↓

FDX

215.59

-12.15%↓

PAYX

153.66

-0.92%↓

CPRT

56.65

-1.58%↓

HEICA

203.75

-4.28%↓

DE

447.26

-4.91%↓

FDX

215.59

-12.15%↓

PAYX

153.66

-0.92%↓

CPRT

56.65

-1.58%↓

HEICA

203.75

-4.28%↓

DE

447.26

-4.91%↓

FDX

215.59

-12.15%↓

PAYX

153.66

-0.92%↓

CPRT

56.65

-1.58%↓

HEICA

203.75

-4.28%↓

DE

447.26

-4.91%↓

FDX

215.59

-12.15%↓

PAYX

153.66

-0.92%↓

CPRT

56.65

-1.58%↓

HEICA

203.75

-4.28%↓

Search

Ocugen Inc

Geschlossen

0.63 -7.35

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.61

Max

0.66

Schlüsselkennzahlen

By Trading Economics

Einkommen

-910K

-14M

Verkäufe

-372K

764K

EPS

-0.05

Gewinnspanne

-1,816.754

Angestellte

95

EBITDA

-603K

-13M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+942.19% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

57M

233M

Vorheriger Eröffnungskurs

7.98

Vorheriger Schlusskurs

0.63

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Ocugen Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

8. Apr. 2024, 14:32 UTC

Wichtige Markttreiber

Ocugen Gets FDA Clearance for IND Amendment for OCU400

Peer-Vergleich

Kursveränderung

Ocugen Inc Prognose

Kursziel

By TipRanks

942.19% Vorteil

12-Monats-Prognose

Durchschnitt 6.67 USD  942.19%

Hoch 8 USD

Tief 4 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Ocugen Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

3 ratings

3

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

0.6351 / 0.7995Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.